Add to ORKGIntroduction: After the initial approval of the use of tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) by the US Food and Drug Administration in 2012 for anti-HIV pre-exposure prophylaxis (PrEP), uptake was initially limited, but more recent community surveys and expert opinion suggest wider acceptance in some key populations. Discussion: Demonstration projects are underway to determine the best practices in the United States to identify at-risk individuals in primary care and sexually transmitted disease clinics who could benefit from PrEP. Studies of PrEP in combination wit
Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretro...
International audienceFollowing US Food and Drugs Administration approval in July 2012 of daily oral...
Background. Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Tru...
Introduction: After the initial approval of the use of tenofovir disoproxil fumarate-emtricitabine (...
Since the beginning of the United States AIDS epidemic in the early 1980s, the medical community has...
ImportanceAn estimated 1.1 million individuals in the United States are currently living with HIV, a...
Despite major advances in the HIV prevention toolbox in the past decade, there remain substantial so...
Pre-exposure prophylaxis (PrEP) is a new strategy for HIV prevention in which HIV-negative individua...
Importance Effective prevention strategies for HIV infection are an important public health priority...
A recent clinical trial demonstrated that a daily dose tenofovir disoproxil fumarate and emtricitabr...
According to the Center for Disease Control and Prevention (CDC), there were 2.1 million new human i...
Preexposure prophylaxis (PrEP) with tenofovir and emtricitabine has been shown to be effective and c...
Abstract Orally administered pre-exposure prophylaxis is an innovative and controversial HIV prevent...
infections per year in the United States, we need more effective HIV prevention strategies. The use ...
Tenofovir-emtricitabine (TDF-FTC) has demonstrated effectiveness as HIV preexposure prophylaxis (PrE...
Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretro...
International audienceFollowing US Food and Drugs Administration approval in July 2012 of daily oral...
Background. Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Tru...
Introduction: After the initial approval of the use of tenofovir disoproxil fumarate-emtricitabine (...
Since the beginning of the United States AIDS epidemic in the early 1980s, the medical community has...
ImportanceAn estimated 1.1 million individuals in the United States are currently living with HIV, a...
Despite major advances in the HIV prevention toolbox in the past decade, there remain substantial so...
Pre-exposure prophylaxis (PrEP) is a new strategy for HIV prevention in which HIV-negative individua...
Importance Effective prevention strategies for HIV infection are an important public health priority...
A recent clinical trial demonstrated that a daily dose tenofovir disoproxil fumarate and emtricitabr...
According to the Center for Disease Control and Prevention (CDC), there were 2.1 million new human i...
Preexposure prophylaxis (PrEP) with tenofovir and emtricitabine has been shown to be effective and c...
Abstract Orally administered pre-exposure prophylaxis is an innovative and controversial HIV prevent...
infections per year in the United States, we need more effective HIV prevention strategies. The use ...
Tenofovir-emtricitabine (TDF-FTC) has demonstrated effectiveness as HIV preexposure prophylaxis (PrE...
Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretro...
International audienceFollowing US Food and Drugs Administration approval in July 2012 of daily oral...
Background. Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Tru...